comparemela.com
Home
Live Updates
Verve Therapeutics Announces Interim Data for VERVE-101 Demo
Verve Therapeutics Announces Interim Data for VERVE-101 Demo
Verve Therapeutics Announces Interim Data for VERVE-101 Demonstrating First Human Proof-of-Concept for In Vivo Base Editing with Dose-Dependent Reductions in LDL-C and Blood PCSK9 Protein in Patients with Heterozygous Familial Hypercholesterolemia
LDL-C Reductions Up to 55% and Blood PCSK9 Protein Reductions Up to 84% Observed After a Single Infusion of VERVE-101 at Potentially Therapeutic Doses Safety Profile Supports Continued Development of...
Related Keywords
United Kingdom ,
Boston ,
Massachusetts ,
United States ,
New York ,
New Zealand ,
Sekar Kathiresan ,
Andrew Bellinger ,
Jen Robinson ,
Ashlea Kosikowski ,
Deepakl Bhatt ,
Safety Profile Supports Continued Development ,
Company To Host Conference Call ,
Exchange Commission ,
Verve Therapeutics Inc ,
Nasdaq ,
Drug Administration ,
Icahn School Of Medicine ,
Observed After ,
Single Infusion ,
Potentially Therapeutic ,
Profile Supports Continued Development ,
Initiate Expansion Cohort ,
Host Conference Call ,
Webcast Today ,
Mount Sinai Fuster Heart Hospital ,
Valentin Fuster Professor ,
Cardiovascular Medicine ,
Icahn School ,
Private Securities Litigation Reform Act ,
Markets ,